title: Cost of Hospital Admissions in Medicare Patients With Atrial Fibrillation Taking Warfarin, Dabigatran, or Rivaroxaban.
authors.forename: Mary S
authors.initials: MS
authors.lastname: Vaughan Sarrazin
authors.forename: Michael
authors.initials: M
authors.lastname: Jones
authors.forename: Alexander
authors.initials: A
authors.lastname: Mazur
authors.forename: Peter
authors.initials: P
authors.lastname: Cram
authors.forename: Padmaja
authors.initials: P
authors.lastname: Ayyagari
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Chrischilles
mesh_terms: D000368:Aged; D000991:Antithrombins / Q000191:economics / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy* / Q000191:economics; D000069604:Dabigatran / Q000191:economics / Q000627:therapeutic use*; D065427:Factor Xa Inhibitors / Q000191:economics / Q000627:therapeutic use; D005260:Female; D017721:Hospital Costs; D006801:Humans; D008297:Male; D006278:Medicare / Q000191:economics*; D010343:Patient Admission / Q000191:economics*; D000069552:Rivaroxaban / Q000191:economics / Q000627:therapeutic use*; D020521:Stroke / Q000209:etiology / Q000517:prevention & control; D014481:United States; D014859:Warfarin / Q000191:economics / Q000627:therapeutic use*
chemical_list: D000991:Antithrombins; D065427:Factor Xa Inhibitors; D014859:Warfarin; D000069552:Rivaroxaban; D000069604:Dabigatran